logo
Plus   Neg
Share
Email

Bayer Proposes Fei-Fei Li & Alberto Weisser To Supervisory Board - Quick Facts

Bayer (BAYZF.PK,BAYRY.PK,BYR.L) said two representatives of the stockholders are to be put forward for election to the Supervisory Board at the Annual Stockholders' Meeting. The independent candidates proposed for election are Fei-Fei Li, an expert in artificial intelligence and Professor in the Computer Science Department at Stanford University in California, and Alberto Weisser, a renowned agricultural expert.

Li and Weisser are intended to succeed Johanna Faber and Wolfgang Plischke, who will not be seeking reelection after their terms of office expire at the end of the Annual Stockholders' Meeting. The company said Li and Weisser are set to be elected for a term of four years.

The company's stockholders will also vote on an adjustment to Supervisory Board compensation. The Board of Management and Supervisory Board are proposing to increase the compensation of Supervisory Board members. The fixed annual compensation is set to rise from 132,000 euros to 160,000 euros.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Nasdaq Inc. (NDAQ) reported Wednesday that its net income for the first quarter grew to $298 million or $1.78 per share from $203 million or $1.22 per share in the prior-year quarter. Excluding items, adjusted net income for the quarter was $327 million or $1.96 per share, compared to $251 million... Guan's Mushroom Co. is recalling all cases of its 200g/7.05-ounce packages of Enoki Mushroom citing the potential to be contaminated with Listeria monocytogenes, the U.S. Food and Drug Administration said. The recalled Enoki is a product of China and comes in a clear plastic package with the description "Enoki Mushroom" in English, Korean and French, and Guan's logo in the front. Shares of Roche were gaining around 2 percent in Swiss trading after the drug major reported Wednesday a 3 percent rise in first-quarter sales at constant currency basis mainly driven by strong growth in Diagnostics Division. Sales, on a reported basis, edged down 1 percent mainly with significant impact from biosimilars. Looking ahead for fiscal 2021, the company continues to expect sales to grow
Follow RTT